StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
CHEMIESYNT.BO$63.66+0.00%
Fair $63.66+0.0%

CHEMIESYNT.BO

CHEMIESYNT.BO

Basic Materials / Specialty ChemicalsBSE

$63.66

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $63.66Fund rank 19/100 · Data gapFallback financials|
SA 29/D
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 14%

FCF escenarios

weak_data · normalized FCF $-19.0M · quality 25.7/100

Data gap 19/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 5/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

29/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. ROE is -1.0%, below the 5% threshold
Thesis & Journal · CHEMIESYNT.BOLocal privado en este navegador · CHEMIESYNT.BO
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$195M

P/E

N/A

•

EV/EBITDA

15.6x

↑

ROE

-1.0%

↓

Gross Margin

73.9%

↑

Debt/Equity

1.37

↑
52-Week Range$64
$31$64

TradingView lightweight chart

CHEMIESYNT.BO price, volumen y niveles de valoración

Último $63.66Periodo +304.2%
Fair value: $63.66

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-14.6%

FCF CAGR

—

FCF margin

2.6%

FCF / Net income

-4.58x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $187.7M · net income $-1.1M · FCF $4.9M

2022-FY → 2025-FY

Gross margin

73.9%+10.5% pts

Operating margin

4.3%-4.1% pts

Net margin

-0.6%-9.6% pts

FCF margin

2.6%+3.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$187.7M$187.7M$162.7M$207.3M$300.8M
Net Income$-1.1M$-1.1M$-3.9M$5.6M$27.2M
EBITDA$21.9M$21.9M$15.5M$25.6M$53.9M
EPS-0.35-0.35-1.261.818.85
Gross Margin73.9%73.9%76.5%70.8%63.4%
Operating Margin4.3%4.3%1.5%6.8%8.4%
Net Margin-0.6%-0.6%-2.4%2.7%9.0%
Balance Sheet
Debt/Equity1.371.371.371.161.04
Cash Flow
Free Cash Flow$4.9M$4.9M$-19.0M$-30.4M$-1.7M
Returns
ROE-1.0%-1.0%-3.4%4.7%24.3%
Valuation
P/E———11.052.05
EV/EBITDA15.6415.6416.197.713.00
P/B1.761.760.840.520.50
Growth & Yield
Revenue Growth15.4%15.4%-21.5%-31.1%—
EPS Growth72.2%72.2%-169.6%-79.5%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +105.5%

Total return

+105.5%

Start / end P/E

n/dx → n/dx

EPS bridge

-1.26 → -0.35

Residual

+105.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+105.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.